OncoMatch/Clinical Trials/NCT06851247
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
Is NCT06851247 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Toripalimab and Anlotinib for nasopharyngeal carcinoma.
Treatment: Toripalimab · Anlotinib · Gemcitabine · Cisplatin — In order to explore the efficacy and safety of targeted therapy and immunotherapy combined with GP chemotherapy in the treatment of high risk advanced nasopharyngeal carcinoma, the investigators design a single-arm, Phase II clinical trial targeted high-risk patients with local stage nasopharyngeal carcinoma (stage IVa: TanyN3M0/T4N0-2M0,8th AJCC/UICC staging) for Toripalimab Plus Anlotinib Combined With GP Induction Chemotherapy and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance Therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage IVA
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: anti-PD-1 therapy
Prior use of anti-PD-1 antibodies
Cannot have received: anti-PD-L1 therapy
Prior use of anti-PD-L1 antibodies
Cannot have received: anti-PD-L2 therapy
Prior use of anti-PD-L2 antibodies
Cannot have received: anti-CTLA-4 therapy
Prior use of anti-CTLA-4 antibodies (or any other antibody that acts on the T-cell co-stimulation or checkpoint pathway)
Lab requirements
Blood counts
Hemoglobin (HGB) ≥90 g/L, white blood cells (WBC) ≥4.0×10^9 /L, platelets (PLT) ≥100×10^9 /L
Kidney function
serum creatinine <1.5×ULN
Liver function
ALT and AST < 2.5 times the upper limit of normal (ULN), total bilirubin <2.0×ULN
Cardiac function
no serious dysfunction of heart
Hemoglobin (HGB) ≥90 g/L, white blood cells (WBC) ≥4.0×10^9 /L, platelets (PLT) ≥100×10^9 /L. Liver function: ALT and AST< 2.5 times the upper limit of normal (ULN), total bilirubin <2.0×ULN. Renal function: serum creatinine <1.5×ULN. no serious dysfunction of heart, lung, liver, kidney and other vital organs.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06851247 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IVA is required.
Is there an age limit?
Yes. Patients must be 65 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages